Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
N Engl J Med
; 390(14): 1290-1298, 2024 Apr 11.
Article
em En
| MEDLINE
| ID: mdl-38477966
ABSTRACT
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos de Linfócitos T
/
Imunoterapia Adotiva
/
Glioblastoma
/
Receptores ErbB
/
Receptores de Antígenos Quiméricos
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article